213 related articles for article (PubMed ID: 37673628)
1. [Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes].
Nakajima H
Rinsho Ketsueki; 2023; 64(8):753-763. PubMed ID: 37673628
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM
Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293
[TBL] [Abstract][Full Text] [Related]
3. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
4. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
Kataoka A; Mizumoto C; Kanda J; Iwasaki M; Sakurada M; Oka T; Fujimoto M; Yamamoto Y; Yamashita K; Nannya Y; Ogawa S; Takaori-Kondo A
Int J Hematol; 2023 Jun; 117(6):919-924. PubMed ID: 36641501
[TBL] [Abstract][Full Text] [Related]
5. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
[TBL] [Abstract][Full Text] [Related]
6. Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome.
Oganesyan A; Hakobyan Y; Terrier B; Georgin-Lavialle S; Mekinian A
Semin Hematol; 2021 Oct; 58(4):247-253. PubMed ID: 34802547
[TBL] [Abstract][Full Text] [Related]
7. Modulating the immune system as a therapeutic target for myelodysplastic syndromes and acute myeloid leukemia.
Putnam C; Kondeti L; Kesler M; Varney M
Biochem Cell Biol; 2023 Dec; 101(6):481-495. PubMed ID: 37566901
[TBL] [Abstract][Full Text] [Related]
8. VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder.
Huang H; Zhang W; Cai W; Liu J; Wang H; Qin T; Xu Z; Li B; Qu S; Pan L; Huang G; Gale RP; Xiao Z
Exp Hematol Oncol; 2021 Mar; 10(1):23. PubMed ID: 33741056
[TBL] [Abstract][Full Text] [Related]
9. Novel combinations to improve hematopoiesis in myelodysplastic syndrome.
Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC
Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
[TBL] [Abstract][Full Text] [Related]
11. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H
Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
[TBL] [Abstract][Full Text] [Related]
12. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
Jachiet V; Ricard L; Hirsch P; Malard F; Pascal L; Beyne-Rauzy O; Peterlin P; Maria ATJ; Vey N; D'Aveni M; Gourin MP; Dimicoli-Salazar S; Banos A; Wickenhauser S; Terriou L; De Renzis B; Durot E; Natarajan-Ame S; Vekhoff A; Voillat L; Park S; Vinit J; Dieval C; Dellal A; Grobost V; Willems L; Rossignol J; Solary E; Kosmider O; Dulphy N; Zhao LP; Adès L; Fenaux P; Fain O; Mohty M; Gaugler B; Mekinian A;
Clin Exp Med; 2023 Jul; 23(3):803-813. PubMed ID: 35953763
[TBL] [Abstract][Full Text] [Related]
13. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
14. [Clinical and genetic features of MDS associated with VEXAS syndrome].
Kunimoto H
Rinsho Ketsueki; 2024; 65(4):255-264. PubMed ID: 38684436
[TBL] [Abstract][Full Text] [Related]
15. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS.
Trowbridge JJ; Starczynowski DT
J Exp Med; 2021 Jul; 218(7):. PubMed ID: 34129017
[TBL] [Abstract][Full Text] [Related]
16. VEXAS syndrome with progression of MDS to MDS/MPN overlap syndrome.
Neupane K; Jayarangaiah A; Zhang Y; Kumar A
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36549759
[TBL] [Abstract][Full Text] [Related]
17. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.
Obiorah IE; Patel BA; Groarke EM; Wang W; Trick M; Ombrello AK; Ferrada MA; Wu Z; Gutierrez-Rodrigues F; Lotter J; Wilson L; Hoffmann P; Cardona DO; Patel N; Dulau-Florea A; Kastner DL; Grayson PC; Beck DB; Young NS; Calvo KR
Blood Adv; 2021 Aug; 5(16):3203-3215. PubMed ID: 34427584
[TBL] [Abstract][Full Text] [Related]
18. VEXAS Syndrome: A Novelty in MDS Landscape.
Templé M; Kosmider O
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885496
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.
Gañán-Gómez I; Wei Y; Starczynowski DT; Colla S; Yang H; Cabrero-Calvo M; Bohannan ZS; Verma A; Steidl U; Garcia-Manero G
Leukemia; 2015 Jul; 29(7):1458-69. PubMed ID: 25761935
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenesis of myelodysplastic syndromes by excessive mitochondrial fragmentation].
Hayashi Y
Rinsho Ketsueki; 2024; 65(4):249-254. PubMed ID: 38684435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]